CL2013003044A1 - Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades. - Google Patents
Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.Info
- Publication number
- CL2013003044A1 CL2013003044A1 CL2013003044A CL2013003044A CL2013003044A1 CL 2013003044 A1 CL2013003044 A1 CL 2013003044A1 CL 2013003044 A CL2013003044 A CL 2013003044A CL 2013003044 A CL2013003044 A CL 2013003044A CL 2013003044 A1 CL2013003044 A1 CL 2013003044A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- tumor
- mps
- triazolo
- leukemias
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11163342 | 2011-04-21 | ||
EP11167872 | 2011-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003044A1 true CL2013003044A1 (es) | 2014-05-02 |
Family
ID=46124297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003044A CL2013003044A1 (es) | 2011-04-21 | 2013-10-21 | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades. |
Country Status (39)
Country | Link |
---|---|
US (1) | US20140120087A1 (es) |
EP (1) | EP2699575B1 (es) |
JP (1) | JP5989091B2 (es) |
KR (1) | KR20140025470A (es) |
CN (1) | CN103608350B (es) |
AP (1) | AP3491A (es) |
AR (1) | AR086191A1 (es) |
AU (1) | AU2012244859B2 (es) |
CA (1) | CA2833657A1 (es) |
CL (1) | CL2013003044A1 (es) |
CO (1) | CO6801751A2 (es) |
CR (1) | CR20130539A (es) |
CY (1) | CY1116439T1 (es) |
DK (1) | DK2699575T3 (es) |
DO (1) | DOP2013000244A (es) |
EA (1) | EA023766B1 (es) |
EC (1) | ECSP13013011A (es) |
ES (1) | ES2539265T3 (es) |
GT (1) | GT201300254A (es) |
HK (1) | HK1190398A1 (es) |
HR (1) | HRP20150517T1 (es) |
HU (1) | HUE025496T2 (es) |
IL (1) | IL228704A0 (es) |
JO (1) | JO3040B1 (es) |
MA (1) | MA35049B1 (es) |
ME (1) | ME02143B (es) |
MX (1) | MX348783B (es) |
MY (1) | MY164939A (es) |
PE (1) | PE20141351A1 (es) |
PL (1) | PL2699575T3 (es) |
PT (1) | PT2699575E (es) |
RS (1) | RS54044B1 (es) |
SA (1) | SA112330466B1 (es) |
SG (1) | SG194003A1 (es) |
SI (1) | SI2699575T1 (es) |
TW (1) | TWI558703B (es) |
UY (1) | UY34034A (es) |
WO (1) | WO2012143329A1 (es) |
ZA (1) | ZA201308707B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20141066A1 (es) | 2011-04-21 | 2014-09-05 | Gilead Sciences Inc | Compuestos de benzotiazol |
UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
CA2867061A1 (en) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
EP2872506A1 (en) * | 2012-07-10 | 2015-05-20 | Bayer Pharma Aktiengesellschaft | Method for preparing substituted triazolopyridines |
WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
CA2914516A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines |
CA2914521A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
BR112015030774A2 (pt) * | 2013-06-10 | 2017-07-25 | Bayer Pharma AG | novos compostos para o tratamento de câncer |
CN105283178A (zh) * | 2013-06-11 | 2016-01-27 | 拜耳制药股份公司 | 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 |
DK3008062T3 (en) | 2013-06-11 | 2017-06-12 | Bayer Pharma AG | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES |
EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
CN107567503B (zh) | 2015-04-17 | 2022-03-22 | 荷兰转化研究中心有限责任公司 | 用于ttk抑制剂化疗的预后生物标记 |
UA125592C2 (uk) * | 2017-03-16 | 2022-04-27 | Джянгсу Хенгруй Медісін Ко., Лтд. | ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ |
EP3956330A4 (en) | 2019-04-18 | 2023-01-18 | The Johns Hopkins University | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
JP2008509965A (ja) | 2004-08-17 | 2008-04-03 | ガルデルマ・リサーチ・アンド・デヴェロップメント | Ppar型受容体を活性化する新規な二芳香族化合物およびその化粧品組成物または医薬組成物における使用 |
US8883820B2 (en) * | 2006-08-30 | 2014-11-11 | Cellzome Ltd. | Triazole derivatives as kinase inhibitors |
CA2693232A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
EA201000341A1 (ru) | 2007-08-23 | 2010-10-29 | Астразенека Аб | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений |
WO2009027283A1 (en) | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
AU2008328882A1 (en) * | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as PI3K inhibitors |
KR20110116160A (ko) | 2009-02-13 | 2011-10-25 | 포비어 파마수티칼스 | 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-a〕피리딘 |
ES2547328T3 (es) | 2009-04-29 | 2015-10-05 | Bayer Intellectual Property Gmbh | Imidazoquinoxalinas sustituidas |
JP5728683B2 (ja) | 2009-09-04 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン |
EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
-
2012
- 2012-04-16 MX MX2013012289A patent/MX348783B/es active IP Right Grant
- 2012-04-16 SI SI201230220T patent/SI2699575T1/sl unknown
- 2012-04-16 JP JP2014505584A patent/JP5989091B2/ja not_active Expired - Fee Related
- 2012-04-16 MA MA36344A patent/MA35049B1/fr unknown
- 2012-04-16 MY MYPI2013701964A patent/MY164939A/en unknown
- 2012-04-16 US US14/113,017 patent/US20140120087A1/en not_active Abandoned
- 2012-04-16 HU HUE12721779A patent/HUE025496T2/en unknown
- 2012-04-16 PT PT127217792T patent/PT2699575E/pt unknown
- 2012-04-16 PE PE2013002378A patent/PE20141351A1/es not_active Application Discontinuation
- 2012-04-16 WO PCT/EP2012/056914 patent/WO2012143329A1/en active Application Filing
- 2012-04-16 SG SG2013073044A patent/SG194003A1/en unknown
- 2012-04-16 ME MEP-2015-80A patent/ME02143B/me unknown
- 2012-04-16 CN CN201280030682.XA patent/CN103608350B/zh not_active Expired - Fee Related
- 2012-04-16 AP AP2013007182A patent/AP3491A/xx active
- 2012-04-16 ES ES12721779.2T patent/ES2539265T3/es active Active
- 2012-04-16 EP EP12721779.2A patent/EP2699575B1/en active Active
- 2012-04-16 EA EA201301181A patent/EA023766B1/ru not_active IP Right Cessation
- 2012-04-16 AU AU2012244859A patent/AU2012244859B2/en not_active Ceased
- 2012-04-16 CA CA2833657A patent/CA2833657A1/en not_active Abandoned
- 2012-04-16 KR KR1020137030546A patent/KR20140025470A/ko not_active Application Discontinuation
- 2012-04-16 PL PL12721779T patent/PL2699575T3/pl unknown
- 2012-04-16 DK DK12721779.2T patent/DK2699575T3/da active
- 2012-04-16 RS RS20150345A patent/RS54044B1/en unknown
- 2012-04-18 JO JOP/2012/0093A patent/JO3040B1/ar active
- 2012-04-18 SA SA112330466A patent/SA112330466B1/ar unknown
- 2012-04-20 AR ARP120101355A patent/AR086191A1/es active Pending
- 2012-04-20 UY UY0001034034A patent/UY34034A/es not_active Application Discontinuation
- 2012-04-20 TW TW101114259A patent/TWI558703B/zh not_active IP Right Cessation
-
2013
- 2013-10-03 IL IL228704A patent/IL228704A0/en unknown
- 2013-10-18 GT GT201300254A patent/GT201300254A/es unknown
- 2013-10-21 CL CL2013003044A patent/CL2013003044A1/es unknown
- 2013-10-21 CR CR20130539A patent/CR20130539A/es unknown
- 2013-10-21 DO DO2013000244A patent/DOP2013000244A/es unknown
- 2013-10-21 CO CO13248763A patent/CO6801751A2/es active IP Right Grant
- 2013-11-05 EC ECSP13013011 patent/ECSP13013011A/es unknown
- 2013-11-20 ZA ZA2013/08707A patent/ZA201308707B/en unknown
-
2014
- 2014-04-15 HK HK14103581.3A patent/HK1190398A1/zh not_active IP Right Cessation
-
2015
- 2015-05-14 HR HRP20150517TT patent/HRP20150517T1/hr unknown
- 2015-06-12 CY CY20151100512T patent/CY1116439T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003044A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades. | |
CL2013002430A1 (es) | Compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de proteina kinasa trk; composicion farmaceutica; compuesto intermediarios; utiles para el tratamiento de carcinoma pailar de tiroides, cancer de pancreas, cancer de colon y carcinoma de mama, entre otras. | |
MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
ZA201700035B (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
DK3808749T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme | |
SI3077397T1 (sl) | 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati | |
CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
IL231591A0 (en) | Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
CL2015000408A1 (es) | Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer. | |
EA201491456A1 (ru) | Соединения-ингибиторы raf | |
DK3489238T3 (da) | Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser | |
CL2015001818A1 (es) | Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras. | |
CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
CR20170315A (es) | Inhibridores bace 1 selectivos | |
CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
CL2014000203A1 (es) | Compuestos derivados de piridin-2(1h) -ona, inhibidores de jak; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de enfermedades mieloproliferativas, leucemia,artritid reumatoide, asma, esclerosis multiplem, entre otras. | |
EP2861608B8 (en) | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide | |
EA201490283A1 (ru) | Соли азабициклических диариловых эфиров и способы их получения или получения их предшественников | |
WO2013188750A3 (en) | Substituted macrocyclic compounds having proteasome inhibitory activity | |
WO2013148638A3 (en) | Compositions and methods related to inhibitors of jak kinase |